Polomar sources active pharmaceutical ingredients, including eletriptan, and manages manufacturing as well as required stability and sterility testing. Delays in these processes and clinical trials have postponed product launch dates. Polomar entered into a Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC (IG4). Under this agreement, ForHumanity holds exclusive marketing rights for the inhalable sildenafil product, VigorAir, through April 30, 2026. Polomar fulfills prescriptions via Polomar Specialty Pharmacy, while IG4 provides account management services. The agreement includes revenue commitments and exclusivity terms, with ForHumanity planning to initiate test marketing of VigorAir in November 2025. ForHumanity Health, Inc. has expressed concerns regarding the efficacy of the inhaled sildenafil product and has decided not to market the metformin gummy. Additionally, ForHumanity Health, Inc. intends to terminate the Product Fulfillment and Distribution Agreement with Polomar.
Polomar Health Services's Comment on Supply Chain
Polomar sources active pharmaceutical ingredients, including eletriptan, and manages manufacturing as well as required stability and sterility testing. Delays in these processes and clinical trials have postponed product launch dates. Polomar entered into a Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC (IG4). Under this agreement, ForHumanity holds exclusive marketing rights for the inhalable sildenafil product, VigorAir, through April 30, 2026. Polomar fulfills prescriptions via Polomar Specialty Pharmacy, while IG4 provides account management services. The agreement includes revenue commitments and exclusivity terms, with ForHumanity planning to initiate test marketing of VigorAir in November 2025. ForHumanity Health, Inc. has expressed concerns regarding the efficacy of the inhaled sildenafil product and has decided not to market the metformin gummy. Additionally, ForHumanity Health, Inc. intends to terminate the Product Fulfillment and Distribution Agreement with Polomar.
Sources:
Polomar Health Services, Inc.'s official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Polomar Health Services, Inc.’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
